Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study - Concepedia

Concepedia

Publication | Open Access

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

DOI Full Paper Access

164

Citations

16

References

2022

Year

Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton, Do‐Youn Oh, Diana L. Hanna, Yoon‐Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee,

The Lancet Oncology

Abstract

Zymeworks.

References

	Year	Citations

Page 1